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Abstract
Comorbid fibromyalgia, in axial spondyloarthritis (axSpA) has been shown to influence disease activity and function, and 
quality of life. Although several papers exist, there is no comprehensive and robust systematic review to determine the 
prevalence of fibromyalgia in this patient group. Thus, the aim of the current study was to provide a definitive estimate of 
prevalence of fibromyalgia in axSpA, and in axSpA sub-classifications. A systematic literature search was conducted in 
Ovid MEDLINE, EMBASE, Evidence Based Medicine (EBM), and Cochrane Library, updated to April 2020, combining 
keywords and relevant MeSH headings, to identify papers reporting the prevalence of fibromyalgia in axSpA, or data from 
which this could be computed. This was then combined in a meta-analysis with data from the Scotland Registry for Anky-
losing Spondylitis (SIRAS), a national axSpA register in Scotland. Data was pooled using random or fixed effects models 
where heterogeneity was greater or lesser than 75%. From 3401 manuscripts initially identified, 15 papers were included in 
the final review, plus SIRAS, giving data from 16 separate sources. The prevalence of fibromyalgia, among a total of 5214 
patients, was 16.4% (95% CI 12.3–20.5%). Prevalence varied with axSpA sub-classification: ankylosing spondylitis: 13.8% 
(9.1–18.6%); MRI positive non-radiographic axSpA 20.3% (6.5–34.1%); and ‘clinical’ disease: 11.1% (6.0–16.2%). Overall, 
around 1 in 6 patients with axSpA also meet criteria for fibromyalgia. While estimates from individual studies vary, comor-
bid fibromyalgia represents a considerable burden across all sub-classifications of axSpA. This emphasises that focusing 
management solely on inflammatory disease in this patient group is unlikely to yield optimal improvements in quality of life.
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Introduction
Comorbid fibromyalgia, in persons with axial spondyloar-
thritis (axSpA), is of considerable and controversial interest. 
Several years ago, the US Food and Drug Administration 
expressed concern that patients with commonly occur-
ring pain conditions, such as fibromyalgia, may be incor-
rectly diagnosed with non-radiographic axSpA (nr-axSpA), 
which in turn may lead to inappropriate treatment with bio-
logic medications. We have previously shown that, among 
patients with axSpA, patients meeting the research criteria 
for fibromyalgia [1] report higher disease activity, poorer 
function and quality of life, and were more likely to report 
high fatigue and moderate or severe levels of mood disorder 
[2]. However, the likelihood of achieving treatment response 
among patients treated with TNF inhibition, did not differ 
between those who did and did not meet criteria for fibro-
myalgia [3].
In a recent systematic review of inflammatory arthritis 
more generally, Duffield and Miller et al. [4] identified nine 
studies reporting the prevalence of fibromyalgia in axSpA 
and/or ankylosing spondylitis (AS). However, their restricted 
search was unlikely to have identified all relevant publica-
tions. Indeed, while they report that nine articles studying 
axSpA were included, a preliminary search has revealed 
several additional important publications that contribute to 
the evidence base.
Using the maximum available data will decrease the 
uncertainty around the prevalence estimate. It also will pro-
vide the rheumatologist with the best evidence in terms of 
likely burden of fibromyalgia in their patient population. 
This may also help to direct resources in terms of patient 
management. Thus, the aim of the current study was to 
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provide a definitive estimate of prevalence of fibromyalgia 
in axSpA through a comprehensive and systematic review 
of the literature, plus the addition of some new primary data.
Over the last decade, the Assessment of Spondyloarthritis 
International Society (ASAS) has led the way in challeng-
ing prior thinking about spondyloarthritis. Now recognised 
as a single disease entity, patients with axSpA can be clas-
sified into different groups: those with only clinical signs 
and symptoms, and no imaging-based evidence of sacro-
iliitis (ASAS clinical criteria), versus those with various 
clinical characteristics with imaging evidence of sacroiliitis 
(ASAS imaging criteria) [5]. The latter group is then further 
sub-classified into those with radiographic changes in the 
sacroiliac joints (AS) versus those with MRI evidence of 
sacroiliitis, but no x-ray changes. Thus, the second aim of 
the current study was to provide estimates of the prevalence 




The conduct and reporting of this meta-analysis were guided 
by the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement [6]. Full-text peer-
reviewed articles were eligible for inclusion based on the 
following criteria:
• Population: Persons with axSpA or AS—classified using 
explicit criteria, or clinical diagnosis. Studies presenting 
data on multiple patient groups were eligible, providing 
the data on axSpA and/or AS could be separately identi-
fied.
• Study design: Any study design. If longitudinal was 
available, data was taken from the timepoint with the 
greatest sample size, with respect to fibromyalgia data.
• Outcome: Either (a) Information on point or period prev-
alence of fibromyalgia—classified using explicit criteria, 
or clinical diagnosis; or (b) Data from which this could 
be computed. Studies presenting data on multiple out-
comes were eligible, providing the data on fibromyalgia 
could be separately identified.
Studies were identified by searching electronic databases; 
Ovid MEDLINE, EMBASE, Evidence Based Medicine 
(EBM), and Cochrane Library up to December 2017. The 
search included the terms:
(1) ankylosing spondylitis (mt) OR ankylosing spondylitis 
(tw) OR spondyloarthritis (mt) OR spondyloarthritis 
(tw) OR spondylarthritis (mt) OR spondylarthritis (tw) 
OR spondyloarthropathies (mt) OR spondyloarthropa-
thies (tw) OR spondyloarthritides (mt) OR spondy-
loarthritides (tw) OR spondylitis (mt) OR spondylitis 
(tw)
(2) fibromyalgia (mt) OR fibromyalgia syndrome (mt)
(3) Boolean combination (1) AND (2)
Reference lists of included articles were also screened for 
inclusion, and update searches were then performed in June 
2019 and April 2020. All the titles were initially screened 
by one reviewer, with 25% of titles checked by a second. 
This resulted in a single additional article taken forward to 
abstract review. Selected abstracts were then screened by 
one reviewer to identify manuscripts to be taken forward 
to full-text review. All excluded abstracts were checked by 
the second reviewer and no additional articles were taken 
forward to full-text review.
Full text articles of all selected abstracts were then 
screened, and a random sample of articles excluded at full 
text screening and all included full texts were independently 
reviewed by the second reviewer. One reviewer extracted 
relevant data from included studies which was independently 
cross-checked by a second reviewer for any transcription or 
interpretation errors. Any disagreements were resolved by 
discussion and consensus.
Scotland Registry for Ankylosing Spondylitis (SIRAS)
The SIRAS protocol has been previously published [7]. In 
brief, patients with a clinical diagnosis of AS were recruited 
from rheumatology departments across Scotland. Eligible 
patients were those who had received a diagnosis of AS 
according to the modified New York criteria [8] or had been 
given a clinical diagnosis of AS by a consultant rheuma-
tologist. Clinical data were collected from medical records, 
and participants completed postal questionnaires containing 
patient-reported measures. At the third follow-up (approxi-
mately 4 years after baseline) questions were included to be 
able to determine whether participants met the American 
College of Rheumatology (ACR) 2011 modification of the 
preliminary diagnostic criteria for fibromyalgia (also known 
as the modified 2010 criteria) [1]. The study was approved 
by the East of Scotland Research Ethics Service (reference: 
16/ES/0030).
Meta‑analysis
For each paper, data on the reported prevalence and the 
sample denominator were used to compute the number of 
individuals with fibromyalgia. (Raw data was taken from the 
paper, if this was available.) Then, an exact 95% confidence 
interval around the prevalence estimate was computed using 
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the method described by Clopper and Pearson [9]. The same 
approach was used for the SIRAS population.
Heterogeneity was quantified using the I2 statistic—i.e. 
the proportion of variation in prevalence estimates between 
studies attributable to heterogeneity, rather than chance. 
Where heterogeneity was judged to be high (I2 ≥ 75%) [10] 
a pooled estimate of fibromyalgia prevalence was obtained 
using a random-effects model, with inverse variance weight-
ing. Where heterogeneity was moderate or low (I2 < 75%) a 
fixed effects model was employed. Separate models were 
produced based on different classifications of fibromyalgia: 
ACR-1990 criteria [16], ACR-2010 [17], ACR-2011 [1] and 
the Fibromyalgia Rapid Screening Tool (FiRST) [12]; and 
also for different classification criteria of axSpA: AS, as 
per the New York or modified New York criteria [8], or the 
ASAS imaging/clinical criteria [5].
Results
Systematic literature review
From 3401 unique publications whose titles were screened, 
312 proceeded to abstract screening, a process which identi-
fied 64 full text articles to screen for eligibility (Fig. 1). Of 
these, 13 manuscripts were deemed eligible for inclusion 
in the review. Two further manuscripts were added after 
Fig. 1  PRISMA flow diagram
1584 Rheumatology International (2020) 40:1581–1591
1 3
screening the reference lists of other papers to provide a 
total of 15 eligible manuscripts/studies.
Eligible studies included 4725 patients, mainly from 
Europe or Israel. Generally, inclusion criteria for older 
studies were defined using clinical diagnosis, or modified 
New York classification of AS; whereas more recent papers 
used ASAS criteria for axSpA either alone or as well as AS. 
Although most studies were published after the 2010 revi-
sion of the ACR fibromyalgia classification criteria, most 
studies measured the outcome using the ACR-1990 criteria. 
A summary of the characteristics of the included studies is 
shown in Table 1.
Prevalence of fibromyalgia in axSpA populations varied 
considerably between studies, and across different classi-
fication criteria both for axSpA and fibromyalgia. There 
was a ten-fold variation in prevalence, from 4.1% (95% CI 
2.5–6.3%) using the ACR-1990 fibromyalgia classification 
criteria, among 462 patients from Spain with AS (modified 
New York criteria) [11], to 41.2% (30.6–52.4%) using the 
Fibromyalgia Rapid Screening Tool (FiRST) [12], among 
526 French / Algerian patients with a clinical diagnosis of 
AS but who failed to meet any ASAS classification criteria 
[13].
Scotland Registry for Ankylosing Spondylitis (SIRAS)
Data were available on 489 participants who completed the 
relevant follow-up questionnaire to allow determination 
of fibromyalgia. 71% of participants were male, and they 
had a mean age of 58 years (SD = 11), with mean (SD) dis-
ease activity and function scores of 4.1 (2.6) and 4.7 (3.1), 
respectively, as determined by the Bath Ankylosing Spondy-
litis Indices for Disease Activity (BASDAI) [14] and Func-
tion (BASFI) [15]. 145 (84%) of persons tested were HLA-
B27 positive, and 130 participants met ACR-2011 research 
criteria for fibromyalgia (26.6%; 22.7–30.7%).
Meta‑analysis
The combination of data from the systematic review, plus 
the SIRAS study population, allowed 5214 individuals, from 
16 studies, to be included in the meta-analysis. There was 
evidence of considerable heterogeneity between studies 
(I2 = 94.0%; p < 0.001) so a random effects analysis was per-
formed. Across all studies, the pooled prevalence of fibro-
myalgia was 16.4% (12.3–20.5%) (Fig. 2). Nine of these 16 
studies defined fibromyalgia using the ACR-1990 criteria. 
Restricting the analysis to these nine (N = 1773) revealed 
a pooled prevalence of 13.6% (8.9–18.4%) (Fig. 3). Three 
studies (N = 536) were identified that used the ACR-2010 
fibromyalgia classification criteria, giving a pooled estimate 
of 21.7% (11.7–31.7%), and two studies that used each of 
the ACR-2011 (N = 1993): 23.4% (17.6–29.1%); and FiRST 
criteria (N = 708): 29.8% (12.7–46.9%) (Fig. 3). A further 
three studies (N = 1131) provided data with fibromyalgia 
classified as per clinical diagnosis. The pooled prevalence 
was 14.4% (5.8–22.9%). 
Ten studies (N = 3003) presented data among patients 
with AS (New York or modified New York classification 
criteria), among whom the pooled estimate of fibromyalgia 
prevalence was 13.8% (9.1–18.6%) (Fig. 4). Prevalence was 
higher among the 520 patients from three studies who met 
ASAS imaging criteria for nr-axSpA: 20.3% (6.5–34.1%), 
but lower among those who only met the ASAS clinical cri-
teria: 11.1% (6.0–16.2%). For the latter model, heterogeneity 
was low (I2 = 0%), so a fixed effects model was used for the 
combined estimate; 4 studies (N = 174).
Discussion
Fibromyalgia in axSpA is common. This meta-analysis, 
including some hitherto unpublished results, shows clear 
and considerable variation in prevalence estimates when 
employing different fibromyalgia classification criteria 
(range 14–30%), and with different axSpA classification 
criteria (range 11–20%). However, overall, we have demon-
strated that around one in six patients with axSpA also meet 
criteria for fibromyalgia.
Our review strategy was comprehensive, covered four 
main bibliographic databases and, although the initial search 
was conducted in December 2017, it was updated to April 
2020. Other databases are available, such as Scopus, Web of 
Science and Google Scholar. While these were not included 
in the search, there is enormous overlap between different 
databases and the probability of missing a full-text peer-
reviewed article relevant to the current review is low. In sup-
port of this, it is reassuring that only two additional studies 
were found from checking the reference lists of the included 
papers—and these were included in the review. Screening 
of manuscript titles was deliberately conservative (i.e. a 
manuscript was only excluded if the reviewer was confident 
that it did not contain relevant information) and the search 
allowed inclusion of studies of any language. For all non-
English studies, an English language title and/or abstract 
was available which permitted screening based on content 
rather than language. No full text studies in a non-English 
language were eligible, so translation was not required. Vari-
ous data were extracted from included studies. Where confi-
dence intervals were presented in the original studies, they 
most commonly utilised the normal approximation of the 
binomial confidence interval. While this is acceptable for 
almost all purposes, in order that the data in Table 1 match 
the output from the meta-analysis, these were recomputed 
as ‘exact’ confidence intervals. Some papers only provided a 
prevalence estimate and total sample size. Thus, the number 
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of participants with fibromyalgia was computed by applying 
the prevalence proportion to the total reported sample and 
rounding to no decimal places (because N must be a posi-
tive integer). This may have introduced a small degree of 
error where missing data was not reported, and this would 
have decreased the standard error of the prevalence estimate 
and increased the weight of the study in the meta-analysis. 
However, for the main findings this only applied to three 
studies, and a sensitivity analysis excluding these studies had 
little effect on the results (fibromyalgia prevalence 17.8% 
(12.7–22.9%)). This suggests that our approach has not 
introduced any major bias.
Over the last decade, the rheumatology community has 
moved away from defining fibromyalgia using widespread 
pain and widespread tenderness on palpation, as per the 
ACR-1990 criteria. Instead, more recent criteria have classi-
fied fibromyalgia based on the presence of widespread pain, 
fatigue, tiredness, cognitive problems, and other common 
symptoms. In total, five methods of classifying fibromyal-
gia were employed across the included studies: ACR-1990, 
2010 and 2011, the FiRST, and clinical diagnosis—and 
often more than one per paper. However, in order to maintain 
independence of observations in the meta-analysis, only one 
estimate could be used in any single pooled estimate. Unsur-
prisingly, the most long-standing classification criteria, the 
ACR-1990 criteria, were employed most commonly, in 
nine out of 15 studies (N = 1773). Therefore, for the overall 
pooled estimate, data on ACR-1990 fibromyalgia took prec-
edence. However, recent studies employing the ACR-2011 
criteria in the UK have been large and, despite comprising 
only two studies, the total patient population (N = 1993) was 
larger. We have shown previously, in the general popula-
tion, that the prevalence of fibromyalgia varies three-fold 
depending on whether the ACR-2011 or ACR-1990 criteria 
Fig. 2  Prevalence of fibromyal-
gia (all studies)
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are employed (5.4% versus 1.7%) [29]. In the current study, 
the difference was less than two-fold, although the absolute 
magnitude of the difference was considerably greater (23% 
versus 14%).
More recent papers employed more recent fibromyalgia 
classification criteria and this, of course, is not unexpected. 
However, the stratification of analysis by fibromyalgia cri-
teria was not a pre-specified analysis. Post hoc analyses 
are a potential concern in meta-analyses reporting treat-
ment effects, and when stratification involves splitting all 
available participant data into sub-groups, by demographic 
characteristics, presence of comorbidities, etc. In the current 
review, sub-grouping was based simply on whether different 
classification criteria were available. It is important to note 
that fibromyalgia classification criteria do not constitute a 
clinical diagnosis, and many patients who meet classification 
criteria may not have been clinically diagnosed. However, 
previously work has shown that, despite this, while patients 
who fulfil the ACR-2011 criteria may not have elevated 
C-reactive protein levels compared to other patients, they 
do report more severe disease (higher disease activity and 
poorer function) as well as high fatigue, and poorer mental 
health and quality of life [2]. They do, therefore, represent a 
specific axSpA sub-group in whom additional management 
is warranted. We believe that the somatic symptoms com-
ponent of the ACR-2011 fibromyalgia criteria may best dis-
tinguish those with/without fibromyalgia and indeed, there 
is evidence that symptoms severity score is a predictor of 
non-response to TNF inhibition [30].
One paper, by Moltó et al. [13], only included patients 
with axSpA in whom their treating physician had decided 
either to commence or switch TNF inhibition [13]. This 
clearly comprises a subset of all axSpA patients and is dis-
tinct from other included studies, which were largely patient 
registries, or series of consecutive patients. However, a sen-
sitivity analysis, excluding the study by Moltó et al. [13] 
Fig. 3  Prevalence of fibromy-
algia (stratified by fibromyalgia 
classification criteria)
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made little difference to the main findings (fibromyalgia 
prevalence 16.4%; 12.0–20.8%), again suggesting that no 
major bias was introduced through the inclusion of this 
study.
The prevalence of fibromyalgia varies markedly in per-
sons with nr-axSpA with/without MRI evidence of sacroili-
itis; the ASAS imaging versus clinical criteria. The current 
study does not address the US Food and Drug Adminis-
tration’s concerns that patients with fibromyalgia may be 
inappropriately classified as nr-axSpA in the current study. 
We show that around 11% of patients who meet the ASAS 
clinical criteria for axSpA experience comorbid fibromyal-
gia, but we cannot comment on the proportion of patients 
with fibromyalgia who have axSpA. However, others have 
demonstrated this to be very low: Baraliakos et al. [18] 
found that, among 100 patients with fibromyalgia, only 2% 
fulfilled the ASAS criteria. Even among those who were 
HLA-B27 positive, prevalence was only 5%. It is also useful 
to remember that patients fulfilling the ASAS clinical crite-
ria are those without a positive image for sacroiliitis. They 
therefore comprise not only those who are imaging negative, 
but also those in whom no image has been taken. Very few 
papers make this distinction.
Our findings are similar to those of Duffield and Miller 
et al. [4], who reported a pooled prevalence in AS of 13% 
(7–19%). These authors acknowledge the presence of addi-
tional papers combining radiological non-radiological 
criteria, although they did not attempt to combine these 
estimates. Here, we adopted a different approach. Recent 
thinking suggests that axSpA may manifest as a spectrum 
of inflammatory spinal disease and thus AS (radiographic 
axSpA) and nr-axSpA, with or without MRI findings, are 
conceptually part of the same disease entity. Although we 
also present separate prevalence estimates for the differ-
ent sub-groups, we therefore believe that a single pooled 
estimate is entirely legitimate, and with additional studies 
Fig. 4  Prevalence of fibro-
myalgia (stratified by axSpA 
classification criteria)
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plus the previously unpublished SIRAS data, we present 
the pooled prevalence estimate with the highest available 
precision.
However, there is still considerable uncertainty around 
some sub-group estimates. The pooled data for patients with 
MRI positive nr-axSpA is based on only 520 patients from 
three studies. As more data becomes available, the preci-
sion from this estimate will improve. Only two studies pre-
sent data on three axSpA classification criteria in the same 
study population [2, 18] but there is no overlap in outcome 
measurement (fibromyalgia criteria). From the description 
of several studies presented here it’s clear that other data is 
available—some authors [19, 20] described their cohorts in 
the context of imaging and clinical arms separately—but do 
not currently provide separate estimates for fibromyalgia, 
nor data from which this can be computed.
In summary, fibromyalgia is a common comorbidity in 
axSpA, experienced by more than one in every six patients. 
Prevalence is similar between those with radiographic dis-
ease (14%) and those with various clinical features but who 
have no imaging evidence of sacroiliitis (11%), whereas 
prevalence is higher among those with MRI-positive nr-
axSpA (20%). However, in all sub-classifications of axSpA 
fibromyalgia represents an important burden. Thus, for a 
sizeable proportion of the patient population, a focus solely 
on reducing the inflammatory aspects of disease are unlikely 
to yield optimal improvements in patient quality of life. 
Here we provide the rheumatologist with the current best 
evidence in terms of likely burden of fibromyalgia in his / 
her axSpA patient population which should be used to help 
direct resources in terms of patient management.
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